Results 61 to 70 of about 1,950 (155)
Journal of International Medical Research, 2023 Objective Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is a prevalent problem affecting hemodialysis (HD) patients. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates
Jie Song +5 more
doaj +1 more source
Journal of Pharmaceutical Health Care and SciencesBackground Based on several case reports and observational studies, there is a growing concern regarding the potential association between roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, and suppression of thyroid function.
Yuki Nakano +3 more
doaj +1 more source
The Journal of Physiology, Volume 604, Issue 12, Page 5031-5060, 15 June 2026.Abstract figure legend Preglomerular pericyte‐like SMMHC+ vascular smooth muscle cells (VSMCs) display marked endocrine plasticity. Hypotension caused by salt depletion and angiotensin‐converting enzyme (ACE) inhibition induces a reversible transformation of these VSMCs toward an endocrine state that produces renin.
Bettina K. M. Firmke +4 more
wiley +1 more source
Roxadustat protects rats from cisplatin-induced acute kidney injury
Purpose: To investigate the potential protective effect of roxadustat against cisplatin-induced acute kidney injury (AKI) by evaluating biochemical markers, inflammatory parameters, renal function tests, and histopathological changes.
Bora, Ejder Saylav +3 more
core +1 more source
HIF‐Regulated Pannexin‐1 Channel Drives Luminal ATP Accumulation in Kidney Cysts
The FASEB Journal, Volume 40, Issue 10, 31 May 2026.Autosomal dominant polycystic kidney disease causes progressive cyst enlargement in the kidneys, leading to hypoxia and induction of HIF‐1α. Our study identifies HIF‐1α‐dependent transcriptional upregulation of Pannexin1 (PANX1) in the apical membrane of cyst epithelial cells, promoting ATP release into the cyst lumen.
Kathrin Skoczynski +10 more
wiley +1 more source
Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice. [PDF]
Front PharmacolIntroductionChronic kidney disease (CKD) often leads to renal anemia, a complication traditionally treated with erythropoiesis-stimulating agents (ESAs) and iron supplementation. However, these treatments may increase cardiovascular risks. Procyanidin, a
Cui M +10 more
europepmc +2 more sources
Journal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.Thalassemia, a common hereditary blood disorder causing impaired globin synthesis and related complications, has seen remarkable progress in recent years due to advancements in genomics and molecular biology. Researchers have identified various gene variants related to thalassemia and improved clinical diagnostic methods, including new genetic testing ...
Chaoqiong Zhou +7 more
wiley +1 more source
, 2021 In patients with chronic kidney disease (CKD), anemia develops gradually, which is primarily due to an inadequate synthesis of erythropoietin by the kidneys, as well as to iron disorders in the body, blood loss, shortened erythrocyte survival and ...
Władysław Grzeszczak +2 more
core +1 more source
Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.This systematic review compiles and analyses 364 studies on chronic kidney disease (CKD) that investigated extracellular vesicles (EVs) for diagnostic and therapeutic applications. By systematically categorizing data according to EV source and cargo, it provides an integrated overview of EV application for CKD, highlighting common approaches and shared
Tunahan Ergunay +2 more
wiley +1 more source